All Releases
 |
Positive Data Presented on Athersys' MultiStem to Treat Stroke
Feb 3, 2012
|
58.4 KB |
|
| |
CLEVELAND and NEW ORLEANS, Feb. 3, 2012 (GLOBE NEWSWIRE) -- Medical researchers from The University of Texas Health Science Center at Houston (UTHealth) Medical School presented new research results this morning at the American Heart Association International Stroke Conference that highlight the role of the spleen in the mechanisms underlying how M...
|
|
Athersys Announces Positive Results of MultiStem(R) Clinical Trial for Hematopoietic Stem Cell Transplant Support and Prevention of Graft-Versus-Host Disease
Feb 1, 2012
|
27.1 KB |
|
| |
CLEVELAND, Feb. 1, 2012 (GLOBE NEWSWIRE) -- Athersys, Inc. (Nasdaq:ATHX) today announced positive results from its Phase I clinical trial of MultiStem®, its cell therapy product, administered to individuals undergoing allogeneic hematopoietic stem cell transplants (HSCT) for the treatment of leukemia and related conditions. According to the Ce...
|
|
Athersys Awarded $3.6 Million in Grant Funding for Stem Cell Product Development
Feb 1, 2012
|
20.7 KB |
|
| |
CLEVELAND, Ohio, Feb. 1, 2012 (GLOBE NEWSWIRE) -- Athersys, Inc. (Nasdaq:ATHX), a leader in the emerging field of regenerative medicine, announced today grant funding aggregating $3.6 million to further advance its MultiStem® product programs and cell therapy platform. Specifically, Athersys was awarded a SBIR Fast-Track grant of up to $1.9 mi...
|
|
Athersys to Present at 2012 Biotech Showcase(TM)
Jan 5, 2012
|
16.4 KB |
|
| |
CLEVELAND, Jan. 5, 2012 (GLOBE NEWSWIRE) -- Athersys, Inc. (Nasdaq:ATHX) announced today that it will present at the 2012 Biotech ShowcaseTM, to be held Monday, January 9 through Wednesday, January 11, 2012, at the Parc 55 Wyndham San Francisco in Union Square. William (B.J.) Lehmann, President and Chief Operating Officer, will be participating and...
|
|
Athersys Receives U.S. Patent Covering the Treatment of Cardiovascular Disease With Adult Stem Cells
Jan 4, 2012
|
18.1 KB |
|
| |
CLEVELAND, Jan. 4, 2012 (GLOBE NEWSWIRE) -- Athersys, Inc. (Nasdaq:ATHX) announced today that it has been granted U.S. patent 8,075,881 that covers the use of non-embryonic multipotent stem cells for the treatment of cardiovascular conditions including myocardial infarction, or heart attack, congestive heart failure, myocardial ischemia and other h...
|
|
Athersys to Present at 23rd Annual Piper Jaffray Health Care Conference
Nov 23, 2011
|
15.5 KB |
|
| |
CLEVELAND, Nov. 23, 2011 (GLOBE NEWSWIRE) -- Athersys, Inc. (Nasdaq:ATHX) announced today that the Company is scheduled to present at the 23rd Annual Piper Jaffray Health Care Conference, to be held Tuesday, November 29 — Wednesday, November 30, 2011, at the New York Palace Hotel in New York City.
William (B.J.) Lehman, President and ...
|
|
Athersys Reports Third Quarter 2011 Results
Nov 14, 2011
|
27.1 KB |
|
| |
CLEVELAND, Nov. 14, 2011 (GLOBE NEWSWIRE) -- Athersys, Inc. (Nasdaq:ATHX), a leader in the emerging field of regenerative medicine, today announced its financial results for the third quarter of 2011. The Company also announced earlier today that it had successfully regained the exclusive rights to MultiStem® for the cardiovascular field throu...
|
|
Athersys Announces Recovery of All Rights to Cardiovascular Cell Therapy Program
Nov 14, 2011
|
20.2 KB |
|
| |
CLEVELAND, Nov. 14, 2011 (GLOBE NEWSWIRE) -- Athersys, Inc. (Nasdaq:ATHX), a leader in the emerging field of regenerative medicine, today announced the termination of its collaboration with Angiotech Pharmaceuticals, Inc. (Angiotech) to co-develop cell therapy in the cardiovascular field. In connection with the mutual termination, Athersys has rega...
|
|
Athersys Enters Into $20 Million Equity Purchase Agreement With Aspire Capital
Nov 14, 2011
|
19.4 KB |
|
| |
CLEVELAND, Nov. 14, 2011 (GLOBE NEWSWIRE) -- Athersys, Inc. (Nasdaq:ATHX), a leader in the emerging field of regenerative medicine, has entered into a Common Stock Purchase Agreement with Aspire Capital Fund, LLC ("Aspire Capital") whereby Aspire Capital has committed to purchase up to $20 million of Athersys' common stock in multiple transactions ...
|
|
Athersys Announces Publication of Phase I Data Regarding MultiStem(R) for Treating Acute Myocardial Infarction
Nov 4, 2011
|
61.6 KB |
|
| |
CLEVELAND, Nov. 4, 2011 (GLOBE NEWSWIRE) -- Athersys, Inc. (Nasdaq:ATHX) announced the online publication today in Circulation Research of results from a Phase I clinical study that found that the delivery of MultiStem® was safe and well tolerated in patients who had recently suffered an acute myocardial infarction (AMI). The data also suggest...
|
|
Athersys and Fast Forward, LLC Enter Collaboration to Support Development of MultiStem to Treat Multiple Sclerosis
Oct 21, 2011
|
22.7 KB |
|
| |
CLEVELAND and NEW YORK, Oct. 21, 2011 (GLOBE NEWSWIRE) -- Athersys, Inc. (Nasdaq:ATHX) and Fast Forward, LLC, a nonprofit subsidiary of the National Multiple Sclerosis Society, announced today an alliance to fund the development of Athersys' MultiStem® adult stem cell platform for the treatment of Multiple Sclerosis (MS), including treatment o...
|
|
Athersys Ranked Number 488 Fastest Growing Company in North America on Deloitte's 2011 Technology Fast 500(TM)
Oct 19, 2011
|
16.0 KB |
|
| |
CLEVELAND, Oct. 19, 2011 (GLOBE NEWSWIRE) -- Athersys, Inc. (Nasdaq:ATHX) today announced it ranked No. 488 on Deloitte's Technology Fast 500™ ranking of the 500 fastest growing technology, media, telecommunications, life sciences and clean technology companies in North America. Athersys' revenue growth during the period covered by the rankin...
|
|
Athersys Confirms Completion of Patient Enrollment for Its Phase I Study of MultiStem(R) for Hematopoietic Stem Cell Transplant Support
Oct 17, 2011
|
20.5 KB |
|
| |
CLEVELAND, Oct. 17, 2011 (GLOBE NEWSWIRE) -- Athersys, Inc. (Nasdaq:ATHX) today announced that it has completed patient enrollment of the repeat dose arm of its clinical study involving administration of MultiStem® to patients being treated for leukemia or other blood born cancers. Initial results from the repeat dose arm of this trial will be...
|
|
Athersys to Present at 18th Annual Newsmakers in the Biotech Industry Conference
Oct 14, 2011
|
15.7 KB |
|
| |
CLEVELAND, Oct. 14, 2011 (GLOBE NEWSWIRE) -- Athersys, Inc. (Nasdaq:ATHX) announced today that Gil Van Bokkelen, Ph.D., Chairman and Chief Executive Officer, will present at the 18th Annual Newsmakers in the Biotech Industry Conference to be held on Friday, October 21, 2011 at 9:00 a.m. Eastern Time at the Millennium Broadway Hotel & Conference Cen...
|
|
Athersys to Host Third Quarter 2011 Financial Results Call
Oct 12, 2011
|
15.7 KB |
|
| |
CLEVELAND, Oct. 12, 2011 (GLOBE NEWSWIRE) -- Athersys, Inc. (Nasdaq:ATHX) today announced it will release its third quarter 2011 financial results at approximately 4:00 p.m. (Eastern Time) on Monday, November 14, 2011, and host a conference call shortly thereafter at 4:30 p.m. (Eastern Time) to review the results. Gil Van Bokkelen, Chairman and Chi...
|
|
Athersys CEO to Deliver Keynote Address at 2011 World Stem Cell Summit
Sep 29, 2011
|
20.8 KB |
|
| |
CLEVELAND, Sept. 29, 2011 (GLOBE NEWSWIRE) -- Gil Van Bokkelen, Chairman and Chief Executive Officer of Athersys, Inc. (Nasdaq:ATHX) and Chairman of the Alliance for Regenerative Medicine based in Washington D.C., will deliver a keynote address during the 7th Annual World Stem Cell Summit in Pasadena, California. His address, entitled "The Transfor...
|
|
Athersys to Present at William Blair & Company's Life Sciences Conference
Sep 6, 2011
|
15.0 KB |
|
| |
CLEVELAND, Sept. 6, 2011 (GLOBE NEWSWIRE) -- Athersys, Inc. (Nasdaq:ATHX) announced today that Gil Van Bokkelen, Ph.D., Chairman and Chief Executive Officer, will speak on a panel discussion titled, "Biotechnology Leadership: Navigating Development-Stage Company Challenges," on Wednesday, September 7, 2011 at 12:10 p.m. Eastern Time at the William ...
|
|
Athersys Reports Second Quarter 2011 Results
Aug 10, 2011
|
25.8 KB |
|
| |
CLEVELAND, Aug. 10, 2011 (GLOBE NEWSWIRE) -- Athersys, Inc. (Nasdaq:ATHX), a leader in the emerging field of regenerative medicine, today announced its financial results for the second quarter of 2011. The Company is successfully developing a portfolio of clinical stage programs involving MultiStem®, a patented non-embryonic stem cell therapy ...
|
|
Athersys to Host Second Quarter 2011 Financial Results Call
Jul 11, 2011
|
15.8 KB |
|
| |
CLEVELAND, July 11, 2011 (GLOBE NEWSWIRE) -- Athersys, Inc. (Nasdaq:ATHX) today announced it will release its second quarter 2011 financial results at approximately 4:00 PM (Eastern Time) on Wednesday, August 10, 2011, and host a conference call shortly thereafter at 4:30 PM (Eastern Time) to review the results. Gil Van Bokkelen, Chairman and Chief...
|
|
One-Year Follow-Up Results From Athersys' Phase I Study of MultiStem in Heart Attack Patients Presented at International Stem Cell Symposium
Jun 13, 2011
|
66.5 KB |
|
| |
CLEVELAND, June 13, 2011 (GLOBE NEWSWIRE) -- Athersys, Inc. (Nasdaq:ATHX) announced positive results from the analysis of one-year follow-up data from its Phase I clinical trial of MultiStem®, its allogeneic adult stem cell product, administered to individuals following acute myocardial infarction (AMI), more commonly referred to as a heart at...
|
|
|
= add release to Briefcase |
|
 |
|
Feb 3, 2012
3:59 PM ET
$1.90  0.03
Quotes delayed at least 20 minutes.
Information provided by eSignal.
|
|
 |
|
